8.5.2026 15:51:12 CEST | Thor Medical ASA | Total number of voting rights and
capital
Reference is made to the stock exchange announcement made by Thor Medical ASA on
5 May 2026 regarding issuance of 219,521 new shares to members of the board.
The share issue has now been registered in the Norwegian Register of Business
Enterprises and the Company's new share capital is NOK 72,000,364 divided into
360,001,820 shares, each with a nominal value of NOK 0.20. Each share represents
one vote in the Company's general meeting.
DISCLOSURE REGULATION
This information is required to be disclosed under Section 5-12 of the
Securities Trading Act.
ABOUT THOR MEDICAL ASA
Thor Medical is an emerging supplier of alpha particle emitters produced from
naturally occurring thorium, a key component of next-generation targeted cancer
treatment. Its proprietary production process requires no irradiation or use of
nuclear reactors, and provides a reliable, environmentally friendly and
cost-efficient supply of alpha emitters to the radiopharmaceutical industry.
Guided by its vision to become a world-leading enabler for targeted cancer
therapies, Thor Medical is committed to improving millions of lives by fueling
next-generation cancer therapies with high-purity isotopes. Thor Medical is
headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange under the
ticker symbol TRMED. For more information, visit www.thormedical.com -
http://www.thormedical.com.
DISCLOSURE REGULATION
This information is required to be disclosed under Section 5-12 of the
Securities Trading Act.
CONTACTS
* Mathias Nilsen Reierth, Head of Communications and Corporate Affairs, +47 988
05 724, mathias.reierth@thormedical.com
ATTACHMENTS
Download announcement as PDF.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/18896548/9604/Download%20announce
ment%20as%20PDF.pdf